Cargando…
Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection
BACKGROUND: During the treatment phase of active pulmonary tuberculosis (PTB), respiratory function impairment is usually restrictive. This may become obstructive, as a PTB-associated airflow obstruction (AFO) or as a later manifestation of underlying COPD. PURPOSE: The aim of the study was to exami...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914072/ https://www.ncbi.nlm.nih.gov/pubmed/27366058 http://dx.doi.org/10.2147/COPD.S106875 |
_version_ | 1782438503784644608 |
---|---|
author | Radovic, Milan Ristic, Lidija Ciric, Zorica Dinic-Radovic, Violeta Stankovic, Ivana Pejcic, Tatjana Rancic, Milan Bogdanovic, Dragan |
author_facet | Radovic, Milan Ristic, Lidija Ciric, Zorica Dinic-Radovic, Violeta Stankovic, Ivana Pejcic, Tatjana Rancic, Milan Bogdanovic, Dragan |
author_sort | Radovic, Milan |
collection | PubMed |
description | BACKGROUND: During the treatment phase of active pulmonary tuberculosis (PTB), respiratory function impairment is usually restrictive. This may become obstructive, as a PTB-associated airflow obstruction (AFO) or as a later manifestation of underlying COPD. PURPOSE: The aim of the study was to examine the potential causes and risks for AFO development in PTB by exploring the aspects of spirometry limitations and clinical implications for the underlying COPD detection, taking into account various confounding factors. PATIENTS AND METHODS: Prospective, nest case–control study on 40 new cases of PTB with initial restrictive respiratory function impairment, diagnosed and treated according to the directly observed treatment short course (DOTS) strategy. RESULTS: From all observed patients, 37.5% of them developed AFO upon the completion of PTB treatment, with significantly increased average of forced vital capacity (%) (P<0.01). Their changes in forced expiratory volume in the first second (%) during the PTB treatment were strongly associated with the air pollution exposure in living (0.474%–20.971% for 95% confidence interval [CI]; P=0.041) and working environments (3.928%–20.379% for 95% CI; P=0.005), initial radiological extent of PTB lesions (0.018%–0.700% for 95% CI; P=0.047), leukocyte count (0.020%–1.328% for 95% CI; P=0.043), and C-reactive protein serum level (0.046%–0.205% for 95% CI; P=0.003) compared to the other patients. The multivariate logistic regression analysis model shows initial radiological extent of pulmonary tuberculosis lesions (OR 1.01–1.05 for 95% CI; P=0.02) and sputum conversion rate on culture (OR 1.02–1.68 for 95% CI; P=0.04) as the most significant predictors for the risk of AFO development. CONCLUSION: AFO upon PTB treatment is a common manifestation of underlying COPD, which mostly occurs later, during the reparative processes in active PTB, even in the absence of major risk factors, such as cigarette smoking and biomass fuel dust exposure. Initial spirometry testing in patients with active PTB is not a sufficient and accurate approach in the detection of underlying COPD, which may lead to their further potential health deterioration. |
format | Online Article Text |
id | pubmed-4914072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49140722016-06-30 Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection Radovic, Milan Ristic, Lidija Ciric, Zorica Dinic-Radovic, Violeta Stankovic, Ivana Pejcic, Tatjana Rancic, Milan Bogdanovic, Dragan Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: During the treatment phase of active pulmonary tuberculosis (PTB), respiratory function impairment is usually restrictive. This may become obstructive, as a PTB-associated airflow obstruction (AFO) or as a later manifestation of underlying COPD. PURPOSE: The aim of the study was to examine the potential causes and risks for AFO development in PTB by exploring the aspects of spirometry limitations and clinical implications for the underlying COPD detection, taking into account various confounding factors. PATIENTS AND METHODS: Prospective, nest case–control study on 40 new cases of PTB with initial restrictive respiratory function impairment, diagnosed and treated according to the directly observed treatment short course (DOTS) strategy. RESULTS: From all observed patients, 37.5% of them developed AFO upon the completion of PTB treatment, with significantly increased average of forced vital capacity (%) (P<0.01). Their changes in forced expiratory volume in the first second (%) during the PTB treatment were strongly associated with the air pollution exposure in living (0.474%–20.971% for 95% confidence interval [CI]; P=0.041) and working environments (3.928%–20.379% for 95% CI; P=0.005), initial radiological extent of PTB lesions (0.018%–0.700% for 95% CI; P=0.047), leukocyte count (0.020%–1.328% for 95% CI; P=0.043), and C-reactive protein serum level (0.046%–0.205% for 95% CI; P=0.003) compared to the other patients. The multivariate logistic regression analysis model shows initial radiological extent of pulmonary tuberculosis lesions (OR 1.01–1.05 for 95% CI; P=0.02) and sputum conversion rate on culture (OR 1.02–1.68 for 95% CI; P=0.04) as the most significant predictors for the risk of AFO development. CONCLUSION: AFO upon PTB treatment is a common manifestation of underlying COPD, which mostly occurs later, during the reparative processes in active PTB, even in the absence of major risk factors, such as cigarette smoking and biomass fuel dust exposure. Initial spirometry testing in patients with active PTB is not a sufficient and accurate approach in the detection of underlying COPD, which may lead to their further potential health deterioration. Dove Medical Press 2016-06-16 /pmc/articles/PMC4914072/ /pubmed/27366058 http://dx.doi.org/10.2147/COPD.S106875 Text en © 2016 Radovic et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Radovic, Milan Ristic, Lidija Ciric, Zorica Dinic-Radovic, Violeta Stankovic, Ivana Pejcic, Tatjana Rancic, Milan Bogdanovic, Dragan Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection |
title | Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection |
title_full | Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection |
title_fullStr | Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection |
title_full_unstemmed | Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection |
title_short | Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection |
title_sort | changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying copd detection |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914072/ https://www.ncbi.nlm.nih.gov/pubmed/27366058 http://dx.doi.org/10.2147/COPD.S106875 |
work_keys_str_mv | AT radovicmilan changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection AT risticlidija changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection AT ciriczorica changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection AT dinicradovicvioleta changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection AT stankovicivana changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection AT pejcictatjana changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection AT rancicmilan changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection AT bogdanovicdragan changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection |